Navigation Links
Genetic mutation may play key role in risk of lethal prostate cancer in overweight patients
Date:12/2/2013

Boston, MA Obesity is associated with a worse prostate cancer prognosis among men whose tumors contain a specific genetic mutation, suggest results from a new study led by Harvard School of Public Health (HSPH), Dana-Farber Cancer Institute and Brigham and Women's Hospital researchers. Among prostate cancer patients whose tumors contain the mutation, they had a more than 50% increased risk of dying from prostate cancer if they were overweight or obese compared to healthy-weight men; among men whose tumors did not have the mutation, there was no effect of obesity on cancer survival. It is the first study to link data on obesity, tumor genetics, and cancer-specific survival in prostate cancer patients.

The study was published online November 30, 2013 in the Journal of the National Cancer Institute.

"More than 100,000 men in the U.S. are diagnosed with prostate cancer that harbors this common gene mutation. Given the high prevalence of obesity among men, this excess risk of lethal prostate cancer associated with obesity is a considerable public health issue," said senior author Lorelei Mucci, associate professor of epidemiology at HSPH.

Prostate cancer is the second leading cause of cancer deaths in men, after lung cancer. In the United States, some 238,000 men will be diagnosed with prostate cancer in 2013. Previous studies have shown that men who are overweight or obeseabout two thirds of the adult male population in the U.S.were more likely to have a worse prognosis after being diagnosed with prostate cancer than normal-weight men, but little was known about the mechanisms of how obesity was linked with prostate cancer or whether specific subgroups of patients were more susceptible to the effects of obesity.

The researchers, including lead author Andreas Pettersson, a former postdoctoral fellow at HSPH and now visiting scholar in the HSPH Department of Epidemiology, Mucci, Massimo Loda at Dana-Farber, and colleagues analyzed data on body mass index (BMI), waist circumference, and a marker for the hormonally regulated genetic mutation TMPRSS2:ERG from 1,243 participants in the Physicians' Health Study and Health Professionals Follow-Up Study who were diagnosed with prostate cancer between 1982 and 2005. Over the course of a follow-up period averaging 13 years, 119 men developed a lethal form of the disease.

One in two men with prostate cancer had tumors that were positive for the common genetic mutation TMPRSS2:ERG. The researchers found that among these men with prostate cancer whose tumors had the mutation, those who were overweight or obese had more than 50% increased risk of dying from cancer after diagnosis than normal-weight men. The effect was even stronger for obesity as measured by waist circumference. In contrast, men whose tumors were negative for the genetic mutation, there was no effect of obesity on cancer survival.

Obesity is associated with higher levels of several hormones, including insulin and growth factors that may fuel the progression of cancer. The authors found for the first time that the men whose tumors contained the TMPRSS2:ERG genetic mutation also had higher levels of the receptors for insulin and growth factor in their tumors. This finding may explain why men whose prostate tumors contain the genetic mutation would be more susceptible to the effects of obesity.

"The results from this study may help us better understand the mechanisms linking obesity with poorer prostate cancer prognosis. The key public health message is unchanged, however: Prostate cancer patients who are overweight or obese should lose weight to increase their chance of survival, regardless of whether their tumors carry this genetic change or not," said Pettersson.


'/>"/>

Contact: Todd Datz
tdatz@hsph.harvard.edu
617-432-8413
Harvard School of Public Health
Source:Eurekalert

Related biology news :

1. Nearby chimpanzee populations show much greater genetic diversity than distant human populations
2. Will a genetic mutation cause trouble? Ask Spliceman
3. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
4. Perception and preference may have genetic link to obesity
5. A foot in the door to genetic information
6. Genetic survey of endangered Antarctic blue whales shows surprising diversity
7. Epigenetic signatures direct the repair potential of reprogrammed cells
8. Epigenetics and epidemiology -- hip, hype and science
9. Genetic variation in East Asians found to explain resistance to cancer drugs
10. First complete full genetic map of promising energy crop
11. Genetic research develops tools for studying diseases, improving regenerative treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology: